Navigation Links
China Pharma Holdings, Inc. to Host Second Quarter 2008 Earnings Conference Call at 10 a.m. EDT Wednesday August 6, 2008
Date:8/1/2008

NEW YORK and HAIKOU, China, Aug. 1 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets leading off-patent brand and newly developed products in China, today announced the Company will host an earning conference call at 10:00 a.m. EDT on Wednesday, August 6, 2008 to discuss these results. The Company also plans to release its earnings earlier that same day.

Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr. Xinhua Wu, Chief Financial Officer, and Mr. Alan Sheinwald, Partner of HC International will be hosting the call. To participate in the conference call, please dial 1-800-591-6945 ten minutes prior to the scheduled conference call time. International callers should dial 1-617-614-4911. The conference pass code is 11374834.

If you are unable to participate in the call at this time, a replay will be available on Wednesday, August 6 at 12:00 p.m. EDT, through Wednesday, August 13. To access the replay, please dial 1-888-286-8010. International callers should dial 1-617-801-6888. The conference pass code is 77875355. This conference call will be broadcast live over the Internet and can be accessed by clicking this link: http://phx.corporate-ir.net/playerlink.zhtml?c=145098&s=wm&e=1914439 . A replay will also be available shortly after the call on China Pharma' website http://www.chinapharmaholdings.com .

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets leading off-patend brand and newly developed products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular, cerebrovascular, CNS, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

Safe Harbor Statement:

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

China Pharma Holdings, Inc.

Sophia Yu

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222

Email: Alan.sheinwald@hcinternational.net


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
2. Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
3. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
4. China-Biotics, Inc. Files Application for Nasdaq Listing
5. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
6. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
7. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
8. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
9. China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandong Province
10. China Agritech to Export Products to Egypt
11. China-Biotics, Inc. to Present at Chinas 3rd Annual Food Safety Technology Forum 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... WARRINGTON, Pa. , Feb. 3, 2016 /PRNewswire/ ... biotechnology company focused on developing aerosolized KL4 surfactant ... Board of Directors has approved an inducement award ... Craig Fraser , its newly appointed President and ... the Board,s Compensation Committee on February 1, 2016 ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered organ ... and bronchus, today announced that CEO Jim ... CEO & Investor Conference on Tuesday, February ... New York City . HART,s presentation ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... validating a series of potential targets (epitopes) specific to misfolded, propagating strains of ... to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from the ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
Breaking Biology News(10 mins):